MCID: PLY020
MIFTS: 44

Polyradiculoneuropathy malady

Category: Neuronal diseases

Aliases & Classifications for Polyradiculoneuropathy

About this section

Aliases & Descriptions for Polyradiculoneuropathy:

Name: Polyradiculoneuropathy 11 49 38 13 67

Classifications:



External Ids:

Disease Ontology11 DOID:4308
SNOMED-CT61 128078004
MeSH38 D011129

Summaries for Polyradiculoneuropathy

About this section
Wikipedia:70 Polyradiculoneuropathy describes a condition in which polyneuropathy and polyradiculopathy occur... more...

MalaCards based summary: Polyradiculoneuropathy is related to lupus erythematosus and hepatitis b. An important gene associated with Polyradiculoneuropathy is PMP22 (Peripheral Myelin Protein 22), and among its related pathways are OX40 Pathway and Cytokines and Inflammatory Response. Affiliated tissues include brain, t cells and skin, and related mouse phenotypes are muscle and digestive/alimentary.

Related Diseases for Polyradiculoneuropathy

About this section

Diseases related to Polyradiculoneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 209)
idRelated DiseaseScoreTop Affiliating Genes
1lupus erythematosus30.5ALB, IL10
2hepatitis b30.0IFNG, IL10, PRF1
3addison's disease29.9IFNG, IL10
4cauda equina syndrome29.6IL10, PRF1
5churg-strauss syndrome29.2ALB, IFNG, IL10, IL17A
6systemic lupus erythematosus29.1ALB, CCL5, IFNG, IL10
7malaria28.3ALB, CCL5, IFNG, IL10, IL17A
8chronic inflammatory demyelinating polyradiculoneuropathy12.1
9polyradiculoneuropathy associated with igg/iga/igm monoclonal gammopathy without known antibodies11.8
10chronic inflammatory demyelinating polyneuropathy11.5
11neuropathy, inflammatory demyelinating11.1
12guillain-barre syndrome11.1
13chronic inflammatory demyelinating polyneuritis10.9
14subacute inflammatory demyelinating polyneuropathy10.9
15chronic polyradiculoneuritis10.8
16hereditary orotic aciduria without megaloblastic anaemia10.7MPZ, PMP22
17headache10.7MPZ, PMP22
18secondary hypertrophic osteoarthropathy10.7MPZ, PMP22
19charcot-marie-tooth neuropathy type 2e/1f10.7MPZ, PMP22
20anal canal adenocarcinoma10.6MPZ, PMP22
21potocki-lupski syndrome10.6MPZ, PMP22
22trachea leiomyoma10.6MPZ, PMP22
23muscle cancer10.6ALB, IFNG
24oral cavity carcinoma in situ10.6ALB, IFNG
25niemann-pick disease, type b10.5MBP, MPZ
26eye accommodation disease10.5IFNG, IL10
27diffuse secondary choroid atrophy10.5ALB, IFNG
28thelaziasis10.5IFNG, IL10
29graft-versus-host disease, protection against10.5IFNG, IL10
30chronic hiccups10.5IFNG, IL10
31buruli ulcer10.5IFNG, IL10
32congestive heart failure10.4MBP, MPZ, PMP22
33hypertonia10.4MBP, MPZ, PMP22
34nevus mucinosis10.4IL10, IL17A
35charcot-marie-tooth disease, type 1e10.4MBP, MPZ, PMP22
36mohr-tranebjaerg syndrome10.4MBP, MPZ, PMP22
37nelson syndrome10.4IFNG, IL10
38acute hemorrhagic encephalitis10.4IFNG, TBX21
39herpangina10.4IFNG, IL10
40epididymo-orchitis10.4IL10, IL17A
41hernia of ovary and fallopian tube10.4IFNG, IL10
42cryptogenic organizing pneumonia10.4ALB, IL17A
43orbit alveolar rhabdomyosarcoma10.4IFNG, IL10
44lipodermatosclerosis10.4IFNG, IL10
45abnormal threshold of rods10.4COL6A1, PMP22
46lesion of sciatic nerve10.4COL6A1, PMP22
47squamous cell papilloma10.4ALB, MPZ, PMP22
48toxocariasis10.4IFNG, IL17A
49autoimmune myocarditis10.4IL17A, STAT3
50cortical dysplasia, complex, with other brain malformations 410.4IL17A, STAT3

Graphical network of the top 20 diseases related to Polyradiculoneuropathy:



Diseases related to polyradiculoneuropathy

Symptoms for Polyradiculoneuropathy

About this section

Drugs & Therapeutics for Polyradiculoneuropathy

About this section

Drugs for Polyradiculoneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
alemtuzumabapproved, investigationalPhase 4303216503-57-0
Synonyms:
Campath
 
MabCampath
alemtuzumab
2AntibodiesPhase 4, Phase 3, Phase 26045
3Rho(D) Immune GlobulinPhase 4, Phase 3, Phase 2317
4Immunoglobulins, IntravenousPhase 4, Phase 3, Phase 2324
5gamma-GlobulinsPhase 4, Phase 3, Phase 2317
6ImmunoglobulinsPhase 4, Phase 3, Phase 26045
7
Prednisoneapproved, vet_approvedPhase 3135953-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
 
Juvason
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
8
Mycophenolate mofetilapproved, investigationalPhase 3939128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
9
Mycophenolic acidapprovedPhase 393924280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
10
Glycineapproved, nutraceutical, vet_approvedPhase 322656-40-6750
Synonyms:
(1-13c)glycinato
(15N)Glycine
15527_RIEDEL
15527_SIAL
15743-44-9 (mono-potassium salt)
17829-66-2 (cobalt salt)
18875-39-3
2,2-dialkylglycines
2-Aminoacetate
2-Aminoacetic acid
2311-65-1
25718-94-9
29728-27-6 (monoammonium salt)
32817-15-5 (copper salt)
33226_RIEDEL
33226_SIAL
33242-26-1 (calcium salt)
35947-07-0 (calcium salt (2:1))
410225_SIAL
50046_FLUKA
50046_SIGMA
513-29-1 (sulfate (3:1))
52955-63-2
56-40-6
57678-19-0
6000-43-7 (hydrochloride)
6000-44-8 (mono-hydrochloride salt)
63183-41-5 (hydrochloride hydrogen carbonate)
71295-98-2 (phosphate (1:1))
7490-95-1 (hydrochloride (2:1)
7490-95-1 (hydrochloride (2:1))
7575-55-5
848646-45-7
87867-94-5
AB-131/40217813
AB1002628
AC1L19XW
AC1Q28JW
AC1Q53O0
AI3-04085
AKOS000119626
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER
AR-1A0345
AR-1A0532
Acide aminoacetique
Acide aminoacetique [INN-French]
Acido aminoacetico
Acido aminoacetico [INN-Spanish]
Acidum aminoaceticum
Acidum aminoaceticum [INN-Latin]
Aciport
Amino-Acetate
Amino-Acetic acid
Aminoacetate
Aminoacetic acid
Aminoazijnzuur
Aminoessigsaeure
Aminoethanoate
Aminoethanoic acid
Amitone
B72BA06C-60E9-4A83-A24A-A2D7F465BB65
BPBio1_001222
Biomol-NT_000195
C00037
CCRIS 5915
CHEBI:15428
CHEBI:15705
CHEBI:16228
CHEMBL773
CID750
CPD-8569
Corilin
D00011
DB00145
EINECS 200-272-2
 
FEMA No. 3287
FT-0083159
G
G0099
G0317
G5417_SIGMA
G5523_SIGMA
G7126_SIGMA
G7403_SIGMA
G8790_SIGMA
G8898_SIGMA
GLY (IUPAC abbrev)
GLYCINE 1.5% IN PLASTIC CONTAINER
GLYCINE, ACS
Glicina
Glicina [INN-Spanish]
Glicoamin
Gly
Glycin
Glycine
Glycine (JP15/USP)
Glycine [INN]
Glycine iron sulphate (1:1)
Glycine, homopolymer (VAN)
Glycine, labeled with carbon-14
Glycine, non-medical
Glycine-UL-14C hydrochloride
Glycinum
Glycinum [INN-Latin]
Glycocoll
Glycolixir
Glycosthene
Glykokoll
Glyzin
Gyn-Hydralin
Gyn-hydralin
H-Gly-OH
H2N-CH2-COOH
HSDB 495
Hampshire glycine
Hgly
InChI=1/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5
KST-1A2919
KST-1A8102
L-Glycine
L-alpha-amino acids
L001246
LS-218
Leimzucker
MolPort-000-871-607
NCGC00024503-01
NCGC00024503-02
NChemBio.2007.13-comp1
NSC 25936
NSC25936
P8791_SIGMA
Padil
Polyglycine II
S04-0135
Sucre de gelatine
Tocris-0219
UNII-TE7660XO1C
W328707_ALDRICH
WLN: Z1VQ
aminoacetic acid
an alpha amino acid ester
bmse000089
gly
glycine
nchem.554-comp2
nchembio.121-comp9
nchembio.145-comp33
nchembio.198-comp12
nchembio.265-comp9
nchembio.266-comp30
polyglycine
11Hormone AntagonistsPhase 3, Phase 212778
12HormonesPhase 3, Phase 213979
13Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 3, Phase 212767
14glucocorticoidsPhase 34920
15Antineoplastic Agents, HormonalPhase 35407
16Fingolimod HydrochloridePhase 387
17Immunosuppressive AgentsPhase 3, Phase 212770
183,4-diaminopyridinePhase 319
19Potassium Channel BlockersPhase 3, Phase 2176
20Anti-Inflammatory AgentsPhase 310355
21Immunoglobulin GPhase 3265
22Pharmaceutical SolutionsPhase 3, Phase 27793
23Anti-Bacterial AgentsPhase 310884
24Antibiotics, AntitubercularPhase 36972
25
4-AminopyridineapprovedPhase 268504-24-51727
Synonyms:
.gamma.-Aminopyridine
275875_ALDRICH
36687_FLUKA
36687_RIEDEL
4 AP
4 Aminopyridine
4 Aminopyridine Sustained Release
4-AP
4-Aminopyridine
4-Aminopyridine 10
4-Aminopyridine Sustained Release
4-Pyridinamine
4-Pyridylamine
4-aminopyridine
5-22-09-00106 (Beilstein Handbook Reference)
504-24-5
A 0152
A0414
A78403_ALDRICH
AB1004971
AC-907/25014071
AC1L1C3R
AC1Q52BM
AI3-52547
AKOS000119896
Amaya
Amino-4 pyridine
Amino-4-Pyridine
Ampydin
Ampyra
Avitrol
Avitrol 200
BB_SC-6974
BRN 0105782
BSPBio_001562
Bio1_000353
Bio1_000842
Bio1_001331
Bio2_000282
Bio2_000762
C13728
C5H6N2
CHEBI:34385
CHEMBL284348
CID1727
Caswell No. 038
Compound 1861
D015761
D04127
Dalfampridine
DivK1c_000572
EINECS 207-987-9
EL-970
EPA Pesticide Chemical Code 069201
EU-0100032
FT-0083754
Fampridina
Fampridine
Fampridine (USAN/INN)
Fampridine SR
Fampridine [USAN:INN]
Fampridine-PR
Fampridine-SR
Fampridinum
HC150041
HMS1361O04
HMS1791O04
HMS1921H15
HMS1989O04
HMS2092F05
HMS501M14
HSDB 6037
IDI1_000572
IDI1_034032
InChI=1/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7
KBio1_000572
 
KBio2_000282
KBio2_000635
KBio2_002850
KBio2_003203
KBio2_005418
KBio2_005771
KBio3_000563
KBio3_000564
KBio3_001888
KBioGR_000282
KBioGR_001505
KBioSS_000282
KBioSS_000635
LS-130202
Lopac-A-0152
Lopac0_000032
MLS000069400
Mi-W-3
MolPort-000-146-022
N07XX07
NCGC00015009-01
NCGC00015009-03
NCGC00015009-12
NCGC00024890-01
NCGC00024890-02
NCGC00024890-03
NCGC00024890-04
NCGC00024890-05
NCGC00024890-06
NCGC00024890-07
NCGC00024890-08
NCGC00024890-09
NCGC00024890-10
NINDS_000572
NSC 15041
NSC15041
Neurelan
Neurelan (TN)
P-Aminopyridine
PYRIDINE,4-AMINO
Philips 1861
Phillips 1861
Pimadin (free base)
Prc 1237
Pymadin
Pymadine
RCRA waste no. P008
SDCCGMLS-0066228.P001
SMR000058211
SPBio_001486
SPECTRUM1501130
STK298717
Spectrum2_001413
Spectrum3_000914
Spectrum4_001013
Spectrum5_001501
Spectrum_000155
Sustained Release, 4-Aminopyridine
TL8003344
Tocris-0940
UNII-BH3B64OKL9
UPCMLD-DP125
UPCMLD-DP125:001
VMI 10-3
VMI 103
VMI-10-3
VMI-103
VMI103
WLN: T6NJ DZ
[J.Pharmacol.Exp.Ther. 275:864 (1995)]
gamma-Aminopyridine
nchem.892-comp4
p-Aminopyridine
p-Aminopyridine [UN2671] [Poison]
p-Aminopyridine [UN2671] [Poison]
pyridin-4-amine
pyridin-4-ylamine
26
Interferon beta-1aapproved, investigationalPhase 2198145258-61-36438354
Synonyms:
145258-61-3
Avonex
Avonex (TN)
Belerofon
D04554
 
Fibroblast interferon
IFN-beta
Interferon beta precursor
Interferon beta-1a
Interferon beta-1a (USAN)
Interferon beta-1a (genetical recombination)
Interferon beta-1a (genetical recombination) (JAN)
27
Folic Acidapproved, nutraceutical, vet_approvedPhase 2427959-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
28Complement System ProteinsPhase 2228
29Thioctic AcidPhase 2115
30Protective AgentsPhase 27190
31Antiviral AgentsPhase 29732
32Vitamin B ComplexPhase 24229
33Adjuvants, ImmunologicPhase 22484
34VitaminsPhase 25095
35MicronutrientsPhase 25802
36Trace ElementsPhase 25802
37Anti-Infective AgentsPhase 221402
38interferonsPhase 22137
39Interferon-betaPhase 2280
40AntioxidantsPhase 22928
41Alpha-lipoic AcidNutraceuticalPhase 2115
42Vitamin B9NutraceuticalPhase 24279
43FolateNutraceuticalPhase 24279
44Vaccines6428
45Chelating Agents1365
46Anticoagulants2516
47Calcium, Dietary5525
48Antibodies, Anti-Idiotypic18
49CitrateNutraceutical1106
50
Citric Acidnutraceutical, vet_approved110677-92-9311
Synonyms:
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Aciletten
Anhydrous citrate
Anhydrous citric acid
Chemfill
Citraclean
 
Citrate
Citretten
Citric acid
Citro
Citronensäure
E 330
Hydrocerol A
Kyselina citronova
Suby G
Uro-trainer
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid

Interventional clinical trials:

(show top 50)    (show all 61)
idNameStatusNCT IDPhase
1Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)Unknown statusNCT01757574Phase 4
2IVIg for Demyelination in Diabetes MellitusRecruitingNCT02372149Phase 4
3Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré SyndromeUnknown statusNCT02221271Phase 3
4Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.CompletedNCT01625182Phase 3
5Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating PolyneuropathyCompletedNCT00004939Phase 3
6Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating NeuropathyCompletedNCT00004286Phase 3
7Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating PolyneuropathyCompletedNCT00004772Phase 3
8Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)CompletedNCT00220740Phase 3
9Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)CompletedNCT01545076Phase 3
10Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.CompletedNCT01824251Phase 3
11Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIgCompletedNCT01349270Phase 3
12Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating PolyneuropathyCompletedNCT01184846Phase 3
13Efficacy and Safety Study of GB-0998 for Guillain-Barré SyndromeCompletedNCT02342184Phase 3
14Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDPRecruitingNCT02955355Phase 3
15Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDPRecruitingNCT02549170Phase 3
16Efficacy and Safety Study of I10E in Treatment of Patients With CIDPRecruitingNCT02293460Phase 3
17Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302RecruitingNCT02317562Phase 3
18Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Active, not recruitingNCT02027701Phase 3
19Interest of Mycophenolate for CIDP WeaningActive, not recruitingNCT02494505Phase 3
20Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDPTerminatedNCT01225276Phase 2, Phase 3
21Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome StudyUnknown statusNCT02029378Phase 2
22Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)CompletedNCT01017159Phase 2
23Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)CompletedNCT00099489Phase 2
24Lipoic Acid to Treat Chronic Inflammatory Demyelinating PolyneuropathyCompletedNCT00962429Phase 2
25Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)CompletedNCT00001287Phase 2
26Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridineCompletedNCT00056810Phase 2
27Early Mechanical Ventilation for Guillain Barré SyndromeCompletedNCT00167622Phase 2
28SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot StudyRecruitingNCT02967679Phase 1, Phase 2
29Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome (GBS) PatientsRecruitingNCT02780570Phase 2
30Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating PolyneuropathyActive, not recruitingNCT00278629Phase 2
31Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating NeuropathyWithdrawnNCT02574962Phase 2
32High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating PolyneuropathyWithdrawnNCT01236456Phase 2
33Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating PolyneuropathyUnknown statusNCT01379833
34Perception and Multisensory Integration in Neurological Patients Using fMRIUnknown statusNCT01469858
35Change of Nerve Conduction Properties in IVIg Dependent NeuropathiesUnknown statusNCT01655394
36Safety Study of GBS Following Menactra Meningococcal VaccinationUnknown statusNCT00575653
37The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin InnervationUnknown statusNCT00173199
38Study of CIDP Patients During IVIG TreatmentCompletedNCT00305266
39MRI in Diagnosing and Monitoring CIDPCompletedNCT02017769
40Effect of Resistance and Aerobic Exercise in CIDP or MMNCompletedNCT02121678
41Immunoglobulin Dosage and Administration Form in CIDP and MMNCompletedNCT02111590
42Effects of Robotic-assisted Gait Training In Non-Ambulatory Patients After Guillain-Barré SyndromeCompletedNCT02883270
43Intravenous Immunoglobulin (IVIG) Versus Plasma Exchange (PE) for Ventilated Children With Guillain Barre Syndrome (GBS)CompletedNCT01306578
44Regional Citrate Anticoagulation in Plasma Exchange TreatmentCompletedNCT01370200
45Brain Computer Interface for Communication in ICU: a Feasibility StudyCompletedNCT01005524
46Peristeen Bowel Irrigation System in Cauda EquinaCompletedNCT01784328
47Prospective Study on Swallowing/Breathing Interactions in Severe Guillain Barre Syndrome.CompletedNCT01024088
48Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating PolyradiculoneuropathyRecruitingNCT02629796
49sCD163 & CD19 as Candidate Biomarkers in CIDP and MMNRecruitingNCT02271724
50Transcriptome Analysis of the Peripheral Blood in CIDPRecruitingNCT02404298

Search NIH Clinical Center for Polyradiculoneuropathy


Cochrane evidence based reviews: polyradiculoneuropathy

Genetic Tests for Polyradiculoneuropathy

About this section

Anatomical Context for Polyradiculoneuropathy

About this section

MalaCards organs/tissues related to Polyradiculoneuropathy:

35
Brain, T cells, Skin, Spinal cord, Thyroid, Tongue, Kidney

Animal Models for Polyradiculoneuropathy or affiliated genes

About this section

MGI Mouse Phenotypes related to Polyradiculoneuropathy:

40
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053699.0ALB, COL6A1, IFNG, IL10, PMP22, STAT3
2MP:00053818.8ALB, IFNG, IL10, IL17A, STAT3, TBX21
3MP:00020068.7ALB, IFNG, IL10, PRF1, STAT3, TBX21
4MP:00036318.2IFNG, IL10, MBP, MPZ, PMP22, PRF1
5MP:00053898.0IFNG, IL10, MBP, MPZ, PMP22, PRF1
6MP:00053848.0ALB, IFNG, IL10, MBP, MPZ, PMP22
7MP:00053767.9ALB, IFNG, IL10, IL17A, MBP, MPZ
8MP:00053977.4CCL5, IFNG, IL10, IL17A, MBP, MPZ
9MP:00053877.3CCL5, IFNG, IL10, IL17A, MBP, MPZ

Publications for Polyradiculoneuropathy

About this section

Articles related to Polyradiculoneuropathy:

(show top 50)    (show all 496)
idTitleAuthorsYear
1
Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. (28084646)
2017
2
Cerebral infarction following subcutaneous immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy. (26873805)
2016
3
Acute inflammatory demyelinating polyradiculoneuropathy in a newborn infant. (27238765)
2016
4
Economic Evaluation of Intravenous Immunoglobulin plus Corticosteroids for the Treatment of Steroid-Resistant Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Thailand. (27113227)
2016
5
Giant nerves in chronic inflammatory polyradiculoneuropathy. (27463360)
2016
6
Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-BarrAc syndrome: a case report. (27380808)
2016
7
Primary Neurolymphomatosis Presenting With Polyradiculoneuropathy Affecting One Lower Limb. (26301373)
2015
8
Triple-stimulation technique improves the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy. (25571892)
2015
9
Chronic inflammatory demyelinating polyradiculoneuropathy with cholesterol deposits in a dog. (26450833)
2015
10
Characteristic MRI features of chronic inflammatory demyelinating polyradiculoneuropathy. (25687202)
2015
11
Somatosensory evoked potentials in chronic inflammatory demyelinating polyradiculoneuropathy. (24887608)
2014
12
Chronic inflammatory demyelinating polyradiculoneuropathy associated intracranial hypertension. (22941356)
2013
13
Chronic inflammatory demyelynating polyradiculoneuropathy in childhood and response to IVIg. (24391437)
2011
14
Sarcoidosis presenting as acute inflammatory demyelinating polyradiculoneuropathy. (21254101)
2011
15
Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. (20133204)
2010
16
Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study. (21040143)
2010
17
Acute polyradiculoneuropathy following wasp sting. (19934578)
2009
18
Ophthalmoplegia, proptosis, and lid retraction caused by cranial nerve hypertrophy in chronic inflammatory demyelinating polyradiculoneuropathy. (17548992)
2007
19
Plasmapheresis for chronic inflammatory demyelinating polyradiculoneuropathy. (17547849)
2007
20
Rituximab therapy in chronic inflammatory demyelinating polyradiculoneuropathy with anti-SGPG IgM antibody. (16814550)
2006
21
European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. (16643309)
2006
22
Biochemical features of chronic inflammatory demyelinating polyradiculoneuropathy]. (16585917)
2006
23
Chronic inflammatory demyelinating polyradiculoneuropathy: new views and guidelines. (16221282)
2005
24
Association between Helicobacter pylori infection and acute inflammatory demyelinating polyradiculoneuropathy. (15679702)
2005
25
Chronic inflammatory demyelinating polyradiculoneuropathy in patients with liver transplantation. (15372442)
2004
26
Diffuse spinal and intercostal nerve involvement in chronic inflammatory demyelinating polyradiculoneuropathy: MRI findings. (16440223)
2003
27
Chronic inflammatory demyelinating polyradiculoneuropathy in diabetic patients. (12661048)
2003
28
Waldenstrom's Macroglobulinaemia Presenting as Demyelinating Polyradiculoneuropathy. (24326654)
2002
29
Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. (11754181)
2002
30
Inflammatory polyradiculoneuropathy with spinal cord involvement and lethal [correction of letal] outcome after hepatitis B vaccination. (11412876)
2001
31
Chronic inflammatory demyelinating polyradiculoneuropathy with histologically proven optic neuritis. (11484826)
2001
32
Treatment approaches for Guillain-BarrAc syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. (11471764)
2001
33
Ataxic form of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). (10809947)
2000
34
Chronic inflammatory demyelinating polyradiculoneuropathy and severe peripheral oedema: a renal explanation. (10844803)
2000
35
Anti-GQ1b and anti-GT1a IgG antibodies in a patient with acute demyelinating polyradiculoneuropathy without ophthalmoplegia. (9328270)
1997
36
A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. (8936360)
1996
37
Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. (7633875)
1995
38
Paralytic illness resembling inflammatory polyradiculoneuropathy in a chimpanzee. (7601702)
1995
39
Glomerulonephritis associated with inflammatory demyelinating polyradiculoneuropathy: a case report and review of the literature. (8502319)
1993
40
Nerve root enhancement with MRI in inflammatory demyelinating polyradiculoneuropathy. (8451012)
1993
41
Prognosis in long-term immunosuppressive treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy. (1738011)
1992
42
Evoked potentials suggest cranial nerves and CNS involvement in chronic relapsing polyradiculoneuropathy. (2731562)
1989
43
Class and IgG subclass distribution of antibodies against peripheral nerve myelin in sera from patients with inflammatory demyelinating polyradiculoneuropathy. (2464267)
1988
44
Absence of antimyelin antibodies and serum demyelinating factors in most patients with chronic inflammatory demyelinating polyradiculoneuropathy. (3267485)
1988
45
Early relapse of acute inflammatory polyradiculoneuropathy after successful treatment with plasma exchange. (3389077)
1988
46
Fulminant leukemic polyradiculoneuropathy in a case of B-cell prolymphocytic leukemia. A clinicopathologic report. (3040217)
1987
47
Chronic nephrotoxicity complicating cyclosporine treatment of chronic inflammatory demyelinating polyradiculoneuropathy. (3796829)
1987
48
Idiopathic inflammatory polyradiculoneuropathy: evaluation of clinical and laboratory data and therapeutic considerations. (6862843)
1983
49
Lymphocyte studies in a patient with chronic polyradiculoneuropathy. (6214729)
1982
50
Polyradiculoneuropathy in Addison's disease. Case report and review of literature. (558557)
1977

Variations for Polyradiculoneuropathy

About this section

Expression for genes affiliated with Polyradiculoneuropathy

About this section
Search GEO for disease gene expression data for Polyradiculoneuropathy.

Pathways for genes affiliated with Polyradiculoneuropathy

About this section

Pathways related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

(show all 16)
idSuper pathwaysScoreTop Affiliating Genes
19.8IFNG, IL10
29.8IFNG, IL10
39.7MBP, MPZ, PMP22
4
Show member pathways
9.4IFNG, IL10, IL17A
5
Show member pathways
9.3IFNG, IL17A, STAT3
69.3IFNG, IL10, STAT3
7
Show member pathways
9.2IFNG, PRF1, STAT3
8
Show member pathways
9.0IFNG, STAT3, TBX21
99.0CCL5, IFNG, IL17A
10
Show member pathways
8.9IFNG, IL10, IL17A, STAT3
118.8IFNG, IL10, IL17A, TBX21
128.6IFNG, PRF1, STAT3, TBX21
13
Show member pathways
8.3IFNG, IL10, IL17A, STAT3, TBX21
14
Show member pathways
8.1CCL5, IFNG, IL10, IL17A, STAT3
15
Show member pathways
7.9IFNG, IL10, IL17A, PRF1, STAT3, TBX21
167.8CCL5, IFNG, IL10, STAT3, TBX21

GO Terms for genes affiliated with Polyradiculoneuropathy

About this section

Cellular components related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1compact myelinGO:004321810.5MBP, PMP22
2myelin sheathGO:00432098.8ALB, MBP, MPZ, PMP2
3extracellular regionGO:00055767.8ALB, CCL5, COL6A1, IFNG, IL17A, PRF1

Biological processes related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1response to mercury ionGO:004668910.4ALB, MBP
2positive regulation of MHC class II biosynthetic processGO:004534810.3IFNG, IL10
3defense response to protozoanGO:004283210.3IFNG, IL10
4positive regulation of interleukin-23 productionGO:003274710.2IFNG, IL17A
5negative regulation of growth of symbiont in hostGO:004413010.2IFNG, IL10
6positive regulation of isotype switching to IgG isotypesGO:004830410.1IFNG, TBX21
7positive regulation of JAK-STAT cascadeGO:00464279.5CCL5, IL10
8response to organic substanceGO:00100339.5ALB, IL10, STAT3
9positive regulation of osteoclast differentiationGO:00456729.5CCL5, IFNG, IL17A
10response to virusGO:00096159.0CCL5, IFNG, TBX21
11agingGO:00075688.6CCL5, IL10, MBP, STAT3
12response to drugGO:00424938.4CCL5, IFNG, IL10, STAT3

Molecular functions related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1fatty acid bindingGO:00055049.7ALB, PMP2
2CCR5 chemokine receptor bindingGO:00317309.1CCL5, STAT3

Sources for Polyradiculoneuropathy

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet